NEW IN SOLEIL RESEARCH™
For decades, intensive induction chemotherapy has been a central frontline strategy for adults with acute myeloid leukemia (AML) who are considered fit enough to tolerate it. The randomized PARADIGM trial asked a consequential question: can the less-intensive combination of azacitidine plus venetoclax produce better disease-control outcomes even in patients who are eligible for conventional induction chemotherapy?
Plain-Language Summary
PARADIGM randomized 172 adults with newly diagnosed AML who were eligible for induction chemotherapy to azacitidine plus venetoclax or conventional induction chemotherapy. Median event-free survival was 14.5 months with azacitidine–venetoclax and 6.2 months with induction chemotherapy. Severe infections and severe bleeding were also less frequent with azacitidine–venetoclax. These findings are important, but they come from a phase 2, open-label trial in a selected AML population. The study was not designed to establish an overall-survival advantage, and several molecularly defined AML groups were excluded.
What Was Studied?
In this multicenter phase 2 trial, previously untreated adults with AML who were considered eligible for induction chemotherapy were randomized 1:1 to azacitidine plus venetoclax or induction chemotherapy. The trial excluded patients with core-binding-factor fusions or FLT3 mutations, and it excluded NPM1-mutated AML in patients younger than 60 years. The prespecified primary endpoint was event-free survival.
The trial enrolled 172 participants, 86 in each treatment group. Median age was 64 years, and 72% of the overall population had adverse-risk disease according to the 2022 European LeukemiaNet classification.
What Did PARADIGM Find?
At a median follow-up of 21.9 months, median event-free survival was 14.5 months with azacitidine–venetoclax versus 6.2 months with induction chemotherapy. The hazard ratio for an event or death was 0.57 (95% CI, 0.39–0.84; P=.002).
Grade 3 or higher infection occurred in 28% of participants receiving azacitidine–venetoclax and 41% receiving induction chemotherapy. Grade 3 or higher hemorrhage occurred in 2% and 12%, respectively. Investigators also reported fewer hospital days during the first 30 days with azacitidine–venetoclax and a higher proportion of patients proceeding to stem-cell transplantation.
Those findings support a meaningful efficacy and treatment-burden signal. They do not, however, establish that azacitidine–venetoclax is superior for every patient with newly diagnosed AML or that it improves overall survival.
Methodological Quality
Soleil Research assessment: MODERATE-HIGH — strong randomized phase 2 evidence, but not definitive phase 3 evidence.
The randomized, multicenter design substantially strengthens causal inference compared with observational comparisons between intensive and lower-intensity AML regimens. The primary endpoint was clinically meaningful and prespecified, and the difference in event-free survival was statistically robust. The population also included a high proportion of patients with adverse-risk disease, making the efficacy signal clinically notable.
At the same time, PARADIGM was open-label and relatively small. Its phase 2 design is better viewed as strong comparative evidence that warrants practice-level attention and confirmatory study rather than as a universal final answer for frontline AML treatment.
Strengths
- Randomized 1:1 comparison against conventional induction chemotherapy.
- Multicenter enrollment across U.S. academic centers.
- Prespecified event-free survival as the primary endpoint.
- Balanced sample size of 86 participants per treatment group.
- Clinically relevant safety outcomes, including severe infection and hemorrhage.
- Evaluation in patients considered fit for intensive treatment, directly testing a long-standing treatment-intensity assumption.
Limitations and Cautions
- This was a phase 2 trial with 172 participants, not a large confirmatory phase 3 trial.
- The open-label design means participants and clinicians knew the assigned treatment, which can influence some care decisions and resource-use outcomes.
- Important molecularly defined groups were excluded, including FLT3-mutated AML, core-binding-factor AML, and younger patients with NPM1-mutated disease. The findings should not be automatically extended to those populations.
- The study was not designed to prove an overall-survival advantage.
- Median follow-up was 21.9 months; longer follow-up remains relevant for durability, transplantation outcomes, late relapse, and survival.
- More patients in the azacitidine–venetoclax arm proceeded to stem-cell transplantation, so downstream outcomes should be interpreted within the complete treatment pathway rather than as a drug-only effect.
Funding and Conflicts of Interest
The investigator-initiated study received support from AbbVie and Genentech, including provision of venetoclax, with additional statistical and data support through the Harvard Cancer Center. The publication and institutional disclosure materials report relevant consulting relationships involving several investigators and companies including AbbVie, Genentech, AstraZeneca, Daiichi Sankyo, Astellas, Servier, Bristol Myers Squibb, BeOne Medicines, Azurity Pharmaceuticals, Thermo Fisher Scientific, Kura, and Syndax.
These relationships do not by themselves invalidate the findings, but they are important context. Randomization and a prespecified primary endpoint reduce several important sources of bias; independent confirmation and longer-term follow-up remain valuable.
Soleil Insight
Treatment intensity is not a synonym for treatment efficacy. PARADIGM provides randomized evidence that a less-intensive regimen can improve event-free survival in a selected population of induction-eligible adults with AML. The appropriate interpretation is narrower than “less-intensive therapy is better for AML”: the signal is strong within the population studied, but phase 2 evidence, molecular exclusions, and the absence of a demonstrated overall-survival advantage argue against universal extrapolation.
Original Publication
Fathi AT, Perl AE, Fell GG, et al. Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. N Engl J Med. 2026;395:845–858. DOI: 10.1056/NEJMoa2602804. PARADIGM trial: NCT04801797.
Featured image: bone marrow smear showing acute myeloid leukemia cells, Makysm/Wikimedia Commons, CC0 1.0. The image is illustrative and is not from a PARADIGM trial participant or study specimen.
Soleil Research™ provides evidence-focused scientific communication and does not substitute for individualized medical care.
Advancing Science. Empowering Humanity.